Compare Stitch Fix Inc (SFIX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Stitch Fix Inc trades at $2.9 (market cap $385.60M), while Vertex Pharmaceuticals Incorporated trades at $521.58 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 347.7× Stitch Fix Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| SFIX | VRTX | |
|---|---|---|
Market Cap | $385.60M | $134.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $5.80 | $557.96 |
52-Week Low | $2.89 | $376.62 |
Enterprise Value | $273.32M | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stitch Fix (SFIX) trades at $2.97, down 2.62% on the day, reflecting ongoing investor caution despite recent operational improvements. The stock is technically bearish with key moving averages signaling selling pressure, while fundamentals show a narrowing net loss margin to -2.27% in 2025 from -9.64% in 2024, alongside a low price-to-sales ratio of 0.3. Recent news highlights AI-driven personalization efforts and exclusive brand collaborations aimed at boosting client engagement and revenue per user.
The outlook remains mixed; cost controls and revenue stabilization offer a path to profitability, but persistent net losses and competitive pressures pose risks. Analyst sentiment is cautious with a 63.64% hold rating, suggesting investors await clearer signs of a sustained turnaround before committing capital.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with an 86% gross margin and 35% net margin, supported by $12.0B revenue in 2025. Recent acquisition of Crinetics Pharmaceuticals expands its pipeline, while analyst consensus remains strongly bullish with an 85.7% buy rating and a $548.78 price target.
Outlook is positive driven by revenue growth and pipeline expansion, but risks include clinical setbacks and competition. The stock offers upside to the consensus target, with cash flow recovery in 2025 signaling operational strength. Investors should weigh high valuation multiples against earnings consistency and market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
